An inexpensive point-of-care immunochromatographic test for Talaromyces marneffei infection based on the yeast phase specific monoclonal antibody 4D1 and Galanthus nivalis agglutinin.
Antibodies, Monoclonal
/ immunology
Antigens, Fungal
/ urine
Antigens, Surface
/ urine
Enzyme-Linked Immunosorbent Assay
/ methods
Gold Colloid
/ chemistry
Humans
Immunoassay
/ methods
Limit of Detection
Mannose-Binding Lectin
/ immunology
Mannose-Binding Lectins
/ immunology
Metal Nanoparticles
/ chemistry
Mycoses
/ diagnosis
Neglected Diseases
/ diagnosis
Plant Lectins
/ immunology
Point-of-Care Testing
Talaromyces
/ immunology
Journal
PLoS neglected tropical diseases
ISSN: 1935-2735
Titre abrégé: PLoS Negl Trop Dis
Pays: United States
ID NLM: 101291488
Informations de publication
Date de publication:
05 2021
05 2021
Historique:
received:
06
08
2020
accepted:
22
12
2020
entrez:
4
5
2021
pubmed:
5
5
2021
medline:
15
9
2021
Statut:
epublish
Résumé
Talaromyces marneffei is a thermally dimorphic fungus that causes opportunistic systemic mycoses in patients with AIDS or other immunodeficiency syndromes. The purpose of this study was to develop an immunochromatographic strip test (ICT) based on a solid phase sandwich format immunoassay for the detection of T. marneffei antigens in clinical urine specimens. The T. marneffei yeast phase specific monoclonal antibody 4D1 (MAb4D1) conjugated with colloidal gold nanoparticle was used as a specific signal reporter. Galanthus nivalis Agglutinin (GNA) was adsorbed onto nitrocellulose membrane to serve as the test line. Similarly, a control line was created above the test line by immobilization of rabbit anti-mouse IgG. The immobilized GNA served as capturing molecule and as non-immune mediated anti-terminal mannose of T. marneffei antigenic mannoprotein. The MAb4D1-GNA based ICT showed specific binding activity with yeast phase antigen of T. marneffei, and it did not react with other common pathogenic fungal antigens. The limit of detection of this ICT for T. marneffei antigen spiked in normal urine was approximately 0.6 μg/ml. The diagnostic performance of the ICT was validated using 341 urine samples from patents with culture- confirmed T. marneffei infection and from a control group of healthy individuals and patients with other infections in an endemic area. The ICT exhibited 89.47% sensitivity, 100% specificity, and 97.65% accuracy. Our results demonstrate that the urine-based GNA-MAb4D1 based ICT produces a visual result within 30 minutes and that the test is highly specific for the diagnosis of T. marneffei infection. The findings validate the deployment of the ICT for clinical use.
Identifiants
pubmed: 33945531
doi: 10.1371/journal.pntd.0009058
pii: PNTD-D-20-01410
pmc: PMC8096094
doi:
Substances chimiques
Antibodies, Monoclonal
0
Antigens, Fungal
0
Antigens, Surface
0
Gold Colloid
0
Mannose-Binding Lectin
0
Mannose-Binding Lectins
0
Plant Lectins
0
snowdrop lectin
0
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
e0009058Subventions
Organisme : NCI NIH HHS
ID : P30 CA008748
Pays : United States
Déclaration de conflit d'intérêts
The authors have declared that no competing interests exist.
Références
Lancet. 1994 Jul 9;344(8915):110-3
pubmed: 7912350
Braz J Microbiol. 2006 Jan;37(1):1-13
pubmed: 20445761
Curr Infect Dis Rep. 2017 Aug 22;19(10):36
pubmed: 28831671
Diagn Microbiol Infect Dis. 2020 Mar;96(3):114959
pubmed: 31836254
J Biol Chem. 1990 Jan 25;265(3):1676-7
pubmed: 2295649
PLoS One. 2015 Jun 17;10(6):e0130376
pubmed: 26083736
J Clin Microbiol. 2007 Sep;45(9):2858-62
pubmed: 17596363
PLoS One. 2018 Apr 5;13(4):e0195569
pubmed: 29621346
Clin Microbiol Rev. 2006 Jan;19(1):95-110
pubmed: 16418525
Int J STD AIDS. 1998 Sep;9(9):555-6
pubmed: 9764944
PLoS One. 2018 Apr 11;13(4):e0195596
pubmed: 29641620
Eur J Clin Microbiol Infect Dis. 2016 Apr;35(4):647-56
pubmed: 26838686
Clin Infect Dis. 1992 Apr;14(4):871-4
pubmed: 1315586
Biosens Bioelectron. 2019 Jul 1;136:60-75
pubmed: 31035028
Clin Infect Dis. 2011 Apr 1;52(7):945-52
pubmed: 21427403
Mycopathologia. 2020 Oct;185(5):893-904
pubmed: 31894499
Med Mycol. 2016 Feb;54(2):162-8
pubmed: 26468550
Molecules. 2015 Jan 05;20(1):519-41
pubmed: 25569512
Emerg Infect Dis. 2015 Jul;21(7):1101-6
pubmed: 26079984
Emerg Microbes Infect. 2016 Mar 09;5:e19
pubmed: 26956447
Anal Biochem. 1976 May 7;72:248-54
pubmed: 942051
J Biol Chem. 1988 Jan 15;263(2):728-34
pubmed: 3335522
Biosensors (Basel). 2019 Jul 17;9(3):
pubmed: 31319629
Med Mycol. 2016 Aug 1;54(6):641-7
pubmed: 27118800
Eukaryot Cell. 2007 Aug;6(8):1400-10
pubmed: 17573547
Lancet Infect Dis. 2017 Nov;17(11):e334-e343
pubmed: 28774701
Diagn Microbiol Infect Dis. 2002 May;43(1):29-37
pubmed: 12052626
Biometrics. 1988 Dec;44(4):1157-68
pubmed: 3233252
Clin Infect Dis. 2008 May 1;46(9):1412-22
pubmed: 18419445
Clin Microbiol Rev. 2011 Apr;24(2):247-80
pubmed: 21482725
J Immunol Methods. 2006 Jan 20;308(1-2):116-23
pubmed: 16403512
J Clin Microbiol. 1998 Apr;36(4):949-54
pubmed: 9542914
J Clin Microbiol. 2017 Aug;55(8):2313-2320
pubmed: 28539345
J Clin Microbiol. 2005 Jun;43(6):2929-31
pubmed: 15956422
BMC Infect Dis. 2013 Oct 05;13:464
pubmed: 24094273
Clin Infect Dis. 2010 Nov 1;51(9):e65-8
pubmed: 20887205
Open Forum Infect Dis. 2019 Oct 11;6(10):ofz208
pubmed: 31660325
Exp Ther Med. 2020 Jan;19(1):160-164
pubmed: 31853286
Clin Infect Dis. 2011 Nov;53(10):1019-23
pubmed: 21940419
Clin Infect Dis. 2010 Dec 15;51(12):1458-62
pubmed: 21054180
Biometrics. 1977 Mar;33(1):159-74
pubmed: 843571
Mycoses. 2016 Dec;59(12):773-780
pubmed: 27453379
Lancet Infect Dis. 2014 Mar;14(3):239-49
pubmed: 24332389
Med Res Rev. 2016 Mar;36(2):221-47
pubmed: 26290041
J Clin Microbiol. 2020 May 26;58(6):
pubmed: 32132194
AIDS Res Ther. 2020 May 26;17(1):26
pubmed: 32456686